iHeart Japan Corporation is developing regenerative medicinal products made from iPS cells,
to save many lives by providing a new medical treatment for heart disease.

 
     
 

News

Aug.19,2016 CEO awarded Japan science council chairman's prize at industry-academia-government collaboration awards.
Jul.8,2016 Interview is appeared in Shachomeikan.
Jun.24,2016 Interview is appeared in Kigyo.tv.
Jun.23,2016 Takara Bio Inc. launches cardiomyocyte product.
May.16,2016 Allocate new shares to third parties.
Jan.25,2016 Acquire a patent in Japan of layering technique.
Dec.16,2015 Acquire a patent in Japan of endothelial.
Oct.21,2015 Acquire a patent in the US of cardiomyocyte marker.
Oct.8,2015 Appeared in Nikkan Kogyo Shimbun, Ltd.  
 
  Past News  
     
     
 
 
 
technology
 
   
 

Cell drugs

Cell drugs
  Related article
Scientific Reports 5, Article number:16842 (20 November 2015)
 
     
 

Research tool

Cell drugs
 
 
Link to Yamashita Laboratory at Center for iPS cell Research and Application (CiRA), Kyoto University
Link to Yamashita Laboratory
 
     
     
 
 
 
about
 
     
 

About us

Trade name
iHeart Japan Corporation
Representative
Kenji Kakuta
Offices Head office
Medical Innovation Center, Kyoto University 53 Kawahara-cho,
Shogoin, Sakyo-ku, Kyoto, 606-8507
Kyoto Mikuruma Laboratory
313 Creation-Core Kyoto Mikuruma 448-5 Kajii-cho,
Kamigyo-ku, Kyoto, 602-0841
Tokyo office
Aios Akihabara 3-2-2 Ueno, Taito-ku, Tokyo,110-0005

Scientific Advisers

Jun Yamashita, Yasuhiko Tabata, Minoru Ono


 
     
 

History

Apr.18,2013 Foundation
Jun.24,2014. Entered into an alliance with Takara Bio Inc.
 
     
     
 
 
 
recruit
 
     
  Organization chart

Message from CEO


Our company is a venture company.
What is a venture company?
We think it is not only a new company, but an entity to change the society better by making a good precedent in the field where no precedent has ever been made.

Large companies have strength in stability.  On the other hand, small venture companies have strenght in flexibility.  Venture companies set precedents by taking risks that large companies are unwilling to take.
Once a precedent is made, a large company can move easily
and spread the precedent rapidly by its big fund and broad network.

That is, a venture company and a large company is in a cooperative relationship
and such a cooperation change the society better.

From the other point of view, venture companies meet social demands of "progress",
and large companies meet social demands of "safety".
Both of them are necessary for society, and there is no superiority among them.

Although there is no superiority, if you choose a venture company, I would like to tell you that;

We desire to be the one who provide a 'future' that people in a "current" never imagine.
The future we desire to provide is that all severe heart failure patients can be treated by excellent cell therapies that realize patients' wishes as "getting back to a healthy life".

If you are willing to make such a future with us, please join us.
 
     
 

Recruiting

 
     
  We welcome whoever has passion and capabilities.
Please send your CV to the address below.

Contact
 
     
     
 
 
 
news
 
     
 

Old News

Aug.19,2016 CEO awarded Japan science council chairman's prize at industry-academia-government collaboration awards
Jun.23,2016 Takara Bio Inc. launches cardiomyocyte product
May.16,2016 Allocate new shares to third parties
Jan.25,2016 Acquire a patent of layering technique in Japan
Dec.16,2015 Acquire a patent of endothelial in Japan
Oct.21,2015 Acquire a patent of cardiomyocyte marker in the US
Apr.24,2015 Awarded a top prize in bio health care area at Rise Up Festa
Feb.27,2015 Awarded a grand prize of Minister of Economy, Trade and Industry at Japan Bio Venture
Feb.17,2015 Awarded a special encouragement prize of medical technology at Japan Venture Awards
Nov.7,2014 Adopted by a commissioned project of Functional development of body tissue manufacturing technology by three dimensional structure of NEDO
Sep.18,2014 Recognized as A-rank company by the committee of connoisseur of venture company, Kyoto city
Sep.5,2014 Allocate new shares to third parties.
Jun.24,2014 Entered into an alliance with Takara Bio Inc.
May.14,2014 Adopted by Innovation Commercialization Venture Support Project of NEDO
Feb.21,2014 Launched collaboration with Nippon Boehringer Ingelheim, Co., Ltd.
Feb.21,2014 Entered into an assignment of patent between Kyoto University